LAWRENCE, Mass., June 26, 2013 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Matthew W. Towse has been appointed Senior Vice President and Chief Financial Officer, and Robert S. Brown, former Senior Vice President and Chief Financial Officer, has been named President of NxStage Kidney Care, Inc., the subsidiary responsible for NxStage's Centers of Excellence initiative. In addition, Kevin Hershberger, NxStage's Controller and Vice President of Finance, has been appointed, to the newly established post of Vice President, Chief Accounting Officer and Controller.
"Matt is a seasoned financial executive with extensive experience aligning the financial and business strategies of high-growth companies. As our new CFO, Matt's leadership will be important as we execute against our strategic growth initiatives," stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage. "This is a positive move that expands and strengthens our management team."
Mr. Towse has over 25 years of experience in global financial management with both public and private companies across multiple industries. He served as Vice President and Chief Financial Officer of Vette Corp., a venture-capital backed global design, engineering and manufacturing technology company from 2006 until its acquisition by a strategic buyer in 2012. From 2003 to 2005, he served as Senior Vice President and Chief Financial Officer of Fairchild Semiconductor International, Inc. Previously, Mr. Towse served as Fairchild's Vice President and Corporate Treasurer from 1997 to 2003, and held various financial management positions with National Semiconductor from 1991 to 1997 before becoming part of the team that spun-out Fairchild from National. Earlier in his career, Mr. Towse was an audit manager with Ernst & Young and most recently, he served as an Interim CFO with Tatum, LLC.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts